Photo courtesy of NCCN

The NCCN 13th Annual Congress: Hematologic Malignancies took place September 21-22, 2018, in New York, N.Y.

CAR T therapy being explored in Hodgkin lymphoma

Print Friendly, PDF & Email


Attendees at the NCCN
13th hematology congress
Photo courtesy of NCCN
Although the data set is small and not yet mature, chimeric antigen receptor (CAR) T-cell therapy appears to be a promising approach for Hodgkin lymphoma, according to Philippe Armand, MD, PhD, of Dana-Farber/Brigham and Women’s Cancer Center and the Massachusetts General Hospital Cancer... [Read Article]
Print Friendly, PDF & Email

Quadruplet therapy could be the future in MM

Print Friendly, PDF & Email


Attendees at the NCCN 13th
hematology congress
Photo courtesy of NCCN
Four-drug combinations are holding promise for the treatment of multiple myeloma (MM), although data from additional randomized trials are needed to define their role in clinical practice, according to Natalie S. Callander, MD, of the University of Wisconsin Carbone Cancer Center. The efficacy of... [Read Article]
Print Friendly, PDF & Email

Ground-breaking therapy comes with distinct challenges

Print Friendly, PDF & Email


Attendees at the 13th NCCN
hematology congress
Photo courtesy of NCCN
Two chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel (Yescarta ®) and tisagenlecleucel (Kymriah™)—are already approved in B-cell lymphoma by the U.S. Food and Drug Administration. A third, lisocabtagene maraleucel, will most likely be approved before too long. Despite differences, they all have high... [Read Article]
Print Friendly, PDF & Email

BCMA-targeted platforms could alter MM therapy

Print Friendly, PDF & Email


Bone marrow aspirate
showing MM
Three novel treatment strategies that target B-cell maturation antigen (BCMA) are showing promise in recent multiple myeloma (MM) clinical trials, according to Shaji K. Kumar, MD, of Mayo Clinic Cancer Center in Rochester, Minnesota. “Clearly, there are a lot of exciting drugs that are currently in clinical trials, but these 3... [Read Article]
Print Friendly, PDF & Email

Novel agents changing treatment algorithm in AML

Print Friendly, PDF & Email


Richard Stone, MD
Photo courtesy of NCCN
Recent drug approvals for acute myeloid leukemia (AML) have greatly expanded options for treating patients, according to a presentation at the NCCN 13th Annual Congress: Hematologic Malignancies. Richard M. Stone, MD, of the Dana-Farber Cancer Institute in Boston, M.A., gave this presentation, providing some guidance for how... [Read Article]
Print Friendly, PDF & Email

Current management of AML patients

Print Friendly, PDF & Email


Attendees at the 13th NCCN
hematology congress
Photo courtesy of NCCN
A presentation at the NCCN 13th Annual Congress: Hematologic Malignancies outlined current practices for managing patients with acute myeloid leukemia (AML). Richard M. Stone, MD, of the Dana-Farber Cancer Institute in Boston, M.A., noted that management of AML now includes increased screening of... [Read Article]
Print Friendly, PDF & Email